These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16611736)

  • 1. CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway.
    Villa I; Mrak E; Rubinacci A; Ravasi F; Guidobono F
    Am J Physiol Cell Physiol; 2006 Sep; 291(3):C529-37. PubMed ID: 16611736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities.
    Wittrant Y; Theoleyre S; Couillaud S; Dunstan C; Heymann D; Rédini F
    Exp Cell Res; 2004 Feb; 293(2):292-301. PubMed ID: 14729467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway.
    Kanematsu M; Yoshimura K; Takaoki M; Sato A
    Bone; 2002 Apr; 30(4):553-8. PubMed ID: 11934645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
    Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parathyroid-hormone-related protein induces expression of receptor activator of NF-{kappa}B ligand in human periodontal ligament cells via a cAMP/protein kinase A-independent pathway.
    Fukushima H; Jimi E; Kajiya H; Motokawa W; Okabe K
    J Dent Res; 2005 Apr; 84(4):329-34. PubMed ID: 15790738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
    Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
    J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
    Evans CE; Mylchreest S; Andrew JG
    BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
    Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
    J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
    Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
    J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol.
    Ishizuka K; Hirukawa K; Nakamura H; Togari A
    Neurosci Lett; 2005 Apr; 379(1):47-51. PubMed ID: 15814197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
    Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
    J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures.
    Lee SK; Lorenzo JA
    Bone; 2002 Jul; 31(1):252-9. PubMed ID: 12110442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture.
    Komine M; Kukita A; Kukita T; Ogata Y; Hotokebuchi T; Kohashi O
    Bone; 2001 May; 28(5):474-83. PubMed ID: 11344046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells.
    Notoya M; Otsuka E; Yamaguchi A; Hagiwara H
    Biochem Biophys Res Commun; 2004 Nov; 324(2):655-60. PubMed ID: 15474477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
    Swanson C; Lorentzon M; Conaway HH; Lerner UH
    Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.